Vutrisiran for transthyretin amyloid cardiomyopathy

Published on 01 Jul 2026
Last Updated on 01 Jul 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Vutrisiran 25 mg/0.5 mL injection for transthyretin amyloid cardiomyopathy.

Funding status

Vutrisiran 25 mg/0.5 mL injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.

Patient must be undergoing treatment with vutrisiran as a monotherapy (i.e. not in combination with any other disease modifying medicines for amyloidosis disorders), and treatment should be used in line with the additional clinical criteria listed in the Annex.

Guidance_Vutrisiran for transthyretin amyloid cardiomyopathy (Published 1 Jul 2026) [PDF, 217.94 KB]

Plain English Summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive condition that occurs when a protein called transthyretin builds up abnormally in the heart. Normally, transthyretin helps carry thyroid hormone and vitamin A through the body. However, when it becomes unstable due to gene changes (mutations) or ageing, it can break down and form deposits, mainly in the heart.

Over time, these deposits cause the heart muscle to become thick and stiff. This makes it harder for the heart to pump blood effectively and can lead to heart failure. Symptoms of ATTR-CM usually develop gradually and may include shortness of breath, fatigue, swelling in the legs or abdomen, and an irregular heartbeat. In some people, transthyretin deposits can also build up in other parts of the body, including the nerves which may cause symptoms such as pain or numbness in the hands, lower back or legs.

Vutrisiran is a medicine known as a transthyretin silencer. It works by reducing the production of the abnormal transthyretin protein that causes deposits in people with ATTR-CM. It is given as an injection under the skin (subcutaneously) and can be self-administered at home.

Vutrisiran was recommended for inclusion in the Medication Assistance Fund (MAF) for government subsidy because its benefit justifies its cost. The treatment cost will be subsidised by 40% to 75% for eligible patients.